The archive · Consumer Apps · Financial decision · 2024–2026
IM8 bets $1B revenue-linked capital on CAC; $200M run rate in 19 months
Beckham-co-founded supplement brand IM8 funds customer acquisition with $1B revenue-linked CVF capital, no dilution; $200M+ run rate in 19 months.
IM8 · Prenetics
What the business is
IM8 is a direct-to-consumer subscription brand selling premium science-backed nutrition drinks — Daily Ultimate Essentials and Daily Ultimate Longevity — co-founded by David Beckham and Danny Yeung as a subsidiary of Nasdaq-listed Prenetics.
Starting capital：$1B growth financing from General Catalyst's Customer Value Fund (closed 2026-07-14): funds up to 70% of IM8's marketing spend per monthly cohort in exchange for a capped share of Reference Income (customer collections × assumed gross margin); no equity, warrants or convertibles issued.
How it started
IM8 launched in December 2024 as a subsidiary of Prenetics, co-founded by Prenetics CEO Danny Yeung and David Beckham after the two met socially. The brand sells premium daily-nutrition drinks by subscription, and from day one built an AI-driven acquisition machine: thousands of live ad experiments, always-on A/B testing of every landing page and funnel, and predictive models scoring cohort lifetime value in near real time.
What happened
IM8 scaled from zero to $200M+ annualized run-rate within 19 months, delivered 50M+ servings (~200K/day, an order every 27 seconds across 43 markets), and posted its strongest month in June 2026 at ~$17M. Every $1 of customer acquisition returned $1.44 in gross profit across mature cohorts. In July 2026 General Catalyst's Customer Value Fund closed a $1B facility financing up to 70% of marketing spend in exchange for a capped share of cohort income, with no equity; Prenetics simultaneously raised FY2026 IM8 revenue guidance to $210–220M, its second increase of the year.
How it ended up
Still scaling: Prenetics expects IM8 to reach a $300M annualized run-rate by end-2026 and $400M+ in FY2027 revenue, with IM8 Hydration (Q4 2026) and a gummies line (Q1 2027) planned.
Background
IM8 is a direct-to-consumer supplement brand co-founded by David Beckham and Danny Yeung, launched in December 2024 as a subsidiary of Nasdaq-listed Prenetics. It sells premium daily-nutrition drinks by subscription — Daily Ultimate Essentials and Daily Ultimate Longevity — and from the start built an AI-native acquisition engine running thousands of live ad tests across 43 markets with always-on A/B testing of funnels.
The bet is that subscriber cohort economics hold at scale: every $1 of customer acquisition has returned $1.44 in gross profit across mature cohorts, so spending aggressively on marketing should compound, not destroy, value. IM8 scaled from zero to a $200M+ annualized run-rate in 19 months, delivered over 50 million servings (about 200,000 per day, an order every 27 seconds), and recorded ~$17M of revenue in June 2026, its strongest month.
In July 2026 General Catalyst's Customer Value Fund closed a $1 billion facility that finances up to 70% of IM8's marketing spend on each monthly cohort in exchange for a capped share of that cohort's income — no equity, warrants or convertibles, no fixed repayment, no covenants. Prenetics raised its FY2026 IM8 revenue guidance to $210–220M and expects a $300M run-rate by year-end 2026 and $400M+ in 2027. The structure only works if the cohort math that General Catalyst underwrote keeps holding as spend scales.
The financing is the product decision itself: Danny Yeung framed it as the answer to a year of investor questions about whether IM8 was spending too much on acquisition — the right question, he argues, was whether it was spending enough.
What has to be true
- The bet is explicit and testable: cohort economics are strong enough that acquisition spend should be maximized, funded by revenue-linked capital instead of equity.
- Numbers are concrete and first-party: 50M+ servings, ~200K/day, $17M June 2026 revenue, $1.44 gross profit per $1 CAC, FY2026 guidance $210–220M, all from the 2026-07-14 Form 6-K.
- The financing structure is a rare, transferable decision: a billion-dollar, non-dilutive facility tied to monthly customer cohorts rather than equity or traditional debt.
- It documents the celebrity-brand growth play with hard operating metrics instead of press-release hype, and the counterintuitive 'spend more' thesis in a market that was questioning CAC.
- There is a visible failure mode: the arrangement only outperforms equity if the $1.44 return on acquisition persists at much larger spend — an open, falsifiable bet.
What can be applied
Proven cohort economics let a brand fund acquisition with revenue-linked capital — no dilution, no fixed repayment; the bet stands or falls on whether the $1.44 CAC return persists at $1B scale.
Aftermath
As of 2026-07-14, IM8 is scaling under the $1B CVF facility: Prenetics raised FY2026 IM8 revenue guidance to $210–220M, expects a $300M annualized run-rate by end-2026 and $400M+ in FY2027, and plans IM8 Hydration (Q4 2026) and a gummies line (Q1 2027). Parent Prenetics (NASDAQ: PRE) reported ~$139.7M in cash and current financial assets as of May 31, 2026. General Catalyst's return is capped per cohort; once it recovers its investment and fixed multiple, all subsequent value accrues to IM8. The open question is whether the CAC-to-gross-profit ratio holds as spend scales.
Sources
- Prenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (Form 6-K)
- David Beckham's health drink startup IM8 takes $1B from General Catalyst's unusual CVF fund
spotted an error? The archive wants to know.
Your turn
You just read one. Describe what you are building, and see who is betting on the same thing.
Free account · 3 free questions · no card